Menu

University:

Pre-Clinical Research Core (PCRC)

The Pre-clinical Research Core plays a central role in the SA OAIC by providing the knowledge, skills, and technical support to assist OAIC investigators in using the common marmoset (Callithrix jacchus) as a pre-clinical model for aging interventions (mainly pharmacological). This core provides to OAIC investigators resources (including access to geriatric marmosets) and services to assist with pre-clinical translation projects, including reverse translational projects to develop novel marmoset models of age-related dysfunction.

Adam B. Salmon, PhD, Core Co-Leader
Cory Ross, PhD, Core Co-Leader

This Core, led by Adam B. Salmon, PhD, and Cory Ross, PhD, supports pre-clinical (animal) projects that explore the basic biology of aging and evaluate interventions that target the aging process to enhance healthy aging, as well as to prevent and better treat aging-related diseases.
 

The Pre-Clinical Research Core can provide to OAIC investigators:

  • Access to a unique colony of aging marmosets.
  • Resources required for studying effects of aging interventions on marmoset healthspan.
  • Tissues collected from marmosets across the age range.
  • Services to assess analytical pharmacology in marmosets.
  • Assistance with research training and dissemination of research as part of the mission of the OAIC.

The Core can also provide functional and physiological assessments of aging marmosets that are unavailable elsewhere as well as the applicable expertise to work with investigators on developing potential projects using aging marmosets.

Marmoset Mother and Baby

 


Below are outlined animal services provided by the Core

– Administration of nutritional or pharmaceutical interventions.

– Tolerability/safety of interventions.

– General physical parameters and animal monitoring.

  • General morphometry (weight, height, waist, chest and appendage circumference)
  • Body composition (Quantitative magnetic resonance (QMR))
  • Physical performance (Strength (lower limb), gait, deficit accumulation)
  • Physical activity (48 hr activity/actimeter)
  • Cognitive/executive function (Detoured reach, conveyor belt)
  • Glucose metabolism (Oral glucose tolerance, insulin concentrations, Hba1c)

– Hematologic assessment:

  • Complete blood cell count
  • Blood lipids

– Assessment of markers of healthspan

  • Inflammation and immune status (T cell subsets and cytokine analysis)
  • Metabolic Function (respirometry, glucose & lipid metabolism assessment)
  • Cardiovascular function (blood pressure, echocardiogram)
  • Sarcopenia
  • Sample collection for “omic” assessment
  • Resilience (marmoset resilience index)

Accomplishments

With our support, investigators have made major advances and novel discoveries in clinical translational geroscience, including:

Ongoing assessment of the effect of rapamycin on marmoset lifespan and healthy aging.

Identification of changes in the aging marmoset gut microbiome.

Identification of significant functional changes in cardiovascular, immune, metabolic, and cognitive function with age in marmosets.

Pharmacological assessment of metformin and acarbose as potential longevity interventions in marmosets.